Rocket Pharmaceuticals, Inc. Finance Lease, Right-of-Use Asset, Amortization
Rocket Pharmaceuticals, Inc. (RCKT) reported Finance Lease, Right-of-Use Asset, Amortization of $1.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $539.00K, a 0.00% change year-over-year.
- Rocket Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $538.00K, a 0.00% change year-over-year.
- Rocket Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $539.00K, a 0.00% change year-over-year.
- Rocket Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $538.00K, a 0.00% change year-over-year.
- Rocket Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $2.15M, a 0.00% change from fiscal 2024.
- Rocket Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $2.15M, a 0.00% change from fiscal 2023.
- Rocket Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $2.15M, a 0.70% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $2.14M, a 0.05% decline from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $539.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.08M 10-Q · filed 2026-08-10 | $1.62M derived: sum of 3 quarters · filed 2026-08-10 | $2.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $538.00K 10-Q · filed 2026-05-07 | $1.08M derived: sum of 2 quarters · filed 2026-05-07 | $1.61M derived: sum of 3 quarters · filed 2026-05-07 | $2.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $539.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.08M derived: sum of 2 quarters · filed 2026-02-26 | $1.62M derived: sum of 3 quarters · filed 2026-08-10 | $2.15M 10-K · filed 2026-02-26 |
| 2025-09-30 | $538.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.08M derived: sum of 2 quarters · filed 2026-08-10 | $1.61M 10-Q · filed 2025-11-06 | $2.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $539.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.08M 10-Q · filed 2026-08-10 | $1.62M derived: sum of 3 quarters · filed 2026-08-10 | $2.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $538.00K 10-Q · filed 2026-05-07 | $1.08M derived: sum of 2 quarters · filed 2026-05-07 | $1.61M derived: sum of 3 quarters · filed 2026-05-07 | $2.15M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $539.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.08M derived: sum of 2 quarters · filed 2026-02-26 | $1.62M derived: sum of 3 quarters · filed 2026-02-26 | $2.15M 10-K · filed 2026-02-26 |
| 2024-09-30 | $538.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.08M derived: sum of 2 quarters · filed 2025-11-06 | $1.61M 10-Q · filed 2025-11-06 | $2.15M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $539.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.08M 10-Q · filed 2025-08-07 | $1.62M derived: sum of 3 quarters · filed 2025-08-07 | $2.15M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $538.00K 10-Q · filed 2025-05-08 | $1.08M derived: sum of 2 quarters · filed 2025-05-08 | $1.61M derived: sum of 3 quarters · filed 2025-05-08 | $2.15M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $539.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.08M derived: sum of 2 quarters · filed 2025-02-27 | $1.62M derived: sum of 3 quarters · filed 2025-02-27 | $2.15M 10-K · filed 2025-02-27 |
| 2023-09-30 | $538.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.08M derived: sum of 2 quarters · filed 2024-11-07 | $1.61M 10-Q · filed 2024-11-07 | $2.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $539.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.08M 10-Q · filed 2024-08-06 | $1.61M derived: sum of 3 quarters · filed 2025-02-27 | $2.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $538.00K 10-Q · filed 2024-05-07 | $1.07M derived: sum of 2 quarters · filed 2025-02-27 | $1.61M derived: sum of 3 quarters · filed 2025-02-27 | $2.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $534.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.07M derived: sum of 2 quarters · filed 2025-02-27 | $1.60M derived: sum of 3 quarters · filed 2025-02-27 | $2.14M 10-K · filed 2025-02-27 |
| 2022-09-30 | $535.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $1.07M derived: sum of 2 quarters · filed 2022-11-04 | $1.60M 10-Q · filed 2022-11-04 | $2.14M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $535.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.07M 10-Q · filed 2022-08-09 | $1.60M derived: sum of 3 quarters · filed 2024-02-27 | $2.14M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $535.00K 10-Q · filed 2022-05-06 | $1.07M derived: sum of 2 quarters · filed 2024-02-27 | $1.60M derived: sum of 3 quarters · filed 2024-02-27 | $2.14M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $535.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.07M derived: sum of 2 quarters · filed 2024-02-27 | $1.60M derived: sum of 3 quarters · filed 2024-02-27 | $2.14M 10-K · filed 2024-02-27 |
| 2021-09-30 | $534.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $1.07M derived: sum of 2 quarters · filed 2021-11-05 | $1.60M 10-Q · filed 2021-11-05 | $2.15M derived: sum of 4 quarters · filed 2021-11-05 |
| 2021-06-30 | $536.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $1.07M 10-Q · filed 2021-08-09 | $1.62M derived: sum of 3 quarters · filed 2021-08-09 | $2.13M derived: sum of 4 quarters · filed 2021-08-09 |
| 2021-03-31 | $535.00K 10-Q · filed 2021-05-10 | $1.08M derived: sum of 2 quarters · filed 2021-05-10 | $1.59M derived: sum of 3 quarters · filed 2021-05-10 | $2.08M derived: sum of 4 quarters · filed 2021-05-10 |
| 2020-12-31 | $545.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.06M derived: sum of 2 quarters · filed 2021-03-01 | $1.55M derived: sum of 3 quarters · filed 2021-03-01 | $1.71M 10-K · filed 2021-03-01 |
| 2020-09-30 | $511.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $1.00M derived: sum of 2 quarters · filed 2020-11-06 | $1.17M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $493.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $655.00K 10-Q · filed 2020-08-05 | ||
| 2020-03-31 | $162.00K 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |